Sorafenib combined with radiotherapy for primary hepatic carcinoma
10.3760/cma.j.issn.1673-422X.2012.08.016
- VernacularTitle:索拉菲尼联合放疗治疗原发性肝癌的研究进展
- Author:
Guangxin LI
;
Jianzhong ZHANG
;
Gong LI
- Publication Type:Journal Article
- Keywords:
Radiotherapy;
Liver neoplasms;
Sorafenib
- From:
Journal of International Oncology
2012;39(8):615-618
- CountryChina
- Language:Chinese
-
Abstract:
Conformal radiotherapy is an important therapeutic strategy for primary hepatic carcinoma,which has high local control rate.However,the frequency of intra- and extra-hepatic recurrences is very high.Sorafenib is the only drug that has been demonstrated effectiveness to increase overall survival in advanced or metastatic hepatocellular carcinoma.The combination about radiotherapy and sorafenib can increase the radiosensitiveness,and inhibit the angiogenesis,and relieve the hypoxia,as well as synchronize the cell cycle.A lot of biological studies of sorafenib combined with radiotherapy have been camied out,and the phase Ⅰ -Ⅱ clinical trials are is in progress.
